(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...
(Date:12/15/2009)... Minn., Dec. 15 The Mosaic Company (NYSE: ... fiscal year 2010 earnings results and financial tables on ... on the New York Stock Exchange. Results will ... ,, The Company will host a conference call with ... the results. The call will begin at 11:00 ...
(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...
(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...
Breaking Biology Technology:Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4... Following the,completion of the Phase II clinical development of ... end of Phase,II meeting with the FDA to discuss ... there was an open and highly constructive discussion with ... the first ever formal discussions with the,agency to license ...
... Holmes Named PartnerLONDON, March 3 Index Ventures ... stage fund, Index Ventures V. The fund is dedicated ... and clean technology sectors across Europe, the United States and ... has raised in the past ten years and reinforces the ...
... Stock Exchange Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), announced that effective on ... purchase warrants, each of which entitles the holder to ... of $5.00 per share, will be extended from March ...
Other Biology Technology:Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3Index Ventures Closes Euro 350 Million Early Stage Fund 2BioMS Medical warrant extension 2Request Info...
Request Info...
Request Info...
... ,ICC and IHC Protocol Development ,Antibody ... Screenings in Animal or Human Cells ... Cells and Tissues ,Peroxidase, Alkaline Phosphatase, ... or Electron Microscopy ,Protein Localization in ...
Biology Products:Biology NavigationMedical Navigation